Imaging techniques for detection of molecular and cellular processes that precede or accompany lung diseases are needed. Matrix metalloproteinases (MMPs) play key roles in the development of pulmonary pathology.
INTRODUCTION
Pulmonary diseases are major causes of morbidity and mortality in the US.
Chronic obstructive pulmonary disease (COPD) alone affects approximately 16 million people and is the fourth leading cause of death in this country [1] [2] [3] . Inflammation is a common and key early player in the pathogenesis of pulmonary diseases, and depending on the trigger and context, can lead to COPD, asthma, pulmonary fibrosis or pulmonary hypertension. Each of these pulmonary diseases is characterized by the presence of an inflammatory infiltrate and a combination of alveolar, airway and vascular remodeling, airways hyper-responsiveness, mucus cell metaplasia, and fibrosis. The interplay of cytokines and growth factors with pulmonary cells mediates the development of pulmonary inflammation and remodeling. An interleukin-13 (IL-13)/ transforming growth factor-β axis appears to be especially important in the pathogenesis of pulmonary fibrosis, asthma and COPD and is under investigation for treatment of remodeling in pulmonary diseases [4] [5] [6] [7] .
Currently, the assessment of progression and response to treatment in COPD and many other pulmonary diseases is based on clinical manifestations, spirometry and anatomic imaging. This overlooks the underlying processes that precede or accompany clinical and physiological alterations. In vivo detection of molecular and cellular processes that are involved in the pathogenesis of pulmonary disease can lead to early diagnosis and help track the effect of therapeutic interventions. Matrix metalloproteinases (MMPs) play prominent roles in pulmonary inflammation and remodeling and have recently emerged as promising novel therapeutic targets in lung disease [8] [9] [10] [11] . A number of pro-inflammatory cytokines (e.g., IL-13) and growth factors by on November 7, 2017 . For personal use only. jnm.snmjournals.org Downloaded from 6 induce MMP expression and activation [11] [12] [13] . Several MMPs are upregulated in response to stimuli (such as smoking) that promote pulmonary inflammation, fibrosis and remodeling 14 . As such detection and quantification of MMP activation in the lungs can potentially provide unique diagnostic and prognostic insight into the course of obstructive and restrictive lung diseases.
In this study we sought to address the feasibility of MMP-targeted molecular imaging for detection of lung inflammation and remodeling. Using transgenic mice that exclusively express IL-13 in the lungs (IL-13 tg), and a 99m Tc-labeled macrocyclic MMPtargeted tracer in conjunction with micro single photon emission tomography (SPECT)-computed tomography (CT) imaging we establish the feasibility of MMP imaging in lung pathology, and investigate the biological correlates of the signal in vivo, demonstrating a strong correlation between MMP activation and lung inflammation.
MATERIALS AND METHODS

Reagents:
Reagents were purchased from Sigma-Aldrich (St. Louis, MI) unless otherwise specified. Recombinant human MMPs were obtained from R&D Systems (Minneapolis, MN).
Animal model: Club cell 10-kDa protein (CC10)-IL-13 Tg mice (n = 21, median age = 10 weeks, range 8-12 weeks) 15 and their transgene-negative, wild-type (WT) littermates (n = 8) were used in this study. In CC10-IL-13 Tg mice IL-13 is specifically targeted to the lung using the CC10 promoter. All experiments were performed under protocols approved by Yale University and VA Connecticut Institutional Animal Care and Use Committees. Fig. 1A ) was synthetized in house as described 16 . Briefly, the RP805 precursor was synthesized from an anti-succinic acid analog, i.e. (2R,3S)-3-(tertbutyoxycarbonyl)-2-iso-butylhe-5-enoic acid in multiple steps. The final product was purified by reversed phase high-performance liquid chromatography (RP-HPLC), identified by analytical RP-HPLC and liquid chromatography-mass spectrometry (data not shown), and tested for its binding affinity (Ki) toward a set of recombinant human MMPs (Supplemental Table) . A new, non-binder amide analog of RP805 precursor (Supplemental Fig. 1B ) was synthesized by replacing the hydroxamate group of RP805 precursor with the N-methyl amide group. As expected, this compound did not show any significant inhibition against recombinant human MMP-12 due to lack of the hydroxamate group. Both compounds were successfully labeled using a non-SnCl2 formulation 17 to give the desired Tc-99m labeled products in high radiochemical yield and radiochemical purity (99%) as confirmed by radio-HPLC.
Affinity measurement: Affinity measurements were based on inhibition of MMPmediated cleavage of a fluorogenic substrate, (7-Methoxycoumarin-4-yl)acetyl-Pro-LeuGly-Leu-Dpa-Ala-Arg-NH2, as described previously 18 .
Imaging: MicroSPECT/CT imaging was performed as described previously with some modification 19 . RP805 (37 MBq) or its 99m Tc-labeled amide analog, as a negative control tracer, were administered through a jugular vein catheter. Image acquisition was performed at 2 hours post-injection with a small animal imaging system (X-SPECT, Gamma Medica-Ideas, Northridge, CA) equipped with 1 mm pinhole collimators. Mice anesthetized with inhaled isoflurane (1%) were placed in a fixed position on the animal by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from 8 bed and microSPECT imaging was performed using the following parameters: 64 projections, 30 sec per projection; 360˚ rotation; matrix 82 X 82; and 140-keV photopeak ± 10% window. Immediately after microSPECT imaging a non-contrast CT image was acquired to provide anatomical data for image quantification. After microSPECT and CT image acquisition the animals were euthanized and lungs, heart and aorta were harvested for planar imaging and histology (the right lung was used for ex vivo imaging and the left lung was snap-frozen in OCT for further RNA and protein analysis). MicroSPECT data were reconstructed and analyzed as described ) using a lysis buffer containing 0.5% Triton X-100 and proteinase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Gelatinase gel zymography was performed on these protein extracts using Novex 10% Zymogram (gelatin) Gels (Life technologies, Carlsbad, CA) according to manufacturer's instructions. Western blotting was performed using an anti-CD68 antibody (Serotec, Raleigh, NC) and quantified as described 21 . For western blot analysis one sample used on two separate gels served as internal control. Band intensities were measured in relation to this internal control.
Tissue binding specificity: Lung tissue sections from CC10-IL-13 Tg mice were exposed to1000-fold (on a molar basis) nonlabeled RP805 precursor or nothing in 100 µL phosphate buffered saline at 37 °C for 2 min, followed by 99m Tc-labeled RP805 (185 kBq) for 15 min in triplicates. Following 3 washes in phosphate buffered saline, the residual activity was measured using a gamma-well counter (PerkinElmer). The data were corrected for protein content and background, and are presented relative to RP805 alone.
Statistical analysis:
Data are presented as mean ± standard deviation. Group comparisons were based on two-tailed Student's t test (for equal variances) or paired ttest (for paired samples). Pearson correlation coefficient was used to test the correlation between variables. Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, Inc, San Diego, CA).
RESULTS
Lung inflammation and remodeling in CC10-IL-13 Tg mice
by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from IL-13 expression in CC10-IL-13 Tg mice led to considerable enlargement of the lungs compared to age-matched WT animals. This difference was readily detectable in animals aged 8 to 13 weeks (Fig.1A) . Histological analysis of the lungs of CC10-IL-13
Tg mice demonstrated loss of normal lung architecture, with alveolar enlargement, inflammatory cell (including macrophage) infiltration, and airway remodeling including airway fibrosis and respiratory epithelial hypertrophy (Fig. 1B-D) . In line with enhanced tissue inflammation, CD68 expression was significantly increased in CC10-IL-13 Tg lungs (Fig. 2) . This was associated with changes in MMP expression (Supplemental Fig.   2 ). As such, compared to WT animals, MMP-12 and MMP-13 were significantly higher in CC10-IL-13 Tg mice (Supplemental Fig. 2C, D) . MMP-2 expression was not different between WT and transgenic animals while for MMP-9 mRNA there was a nonstatistically significant trend in the opposite direction. Pointing to the complexity of the regulation of MMP function in vivo, which depends on MMP expression level, activation state and presence of tissue inhibitors of MMPs (TIMPs), TIMP-1 expression was significantly higher in CC10-IL-13 Tg lungs (Supplemental Fig. 2E ) while there was no difference between transgenic and WT animals in TIMP-2 and TIMP-3 mRNA expression. Evaluation of lung extracts by gel zymography showed distinct bands corresponding to MMP-2 and MMP-9 gelatinolytic activity. In this regard, while there was no difference in MMP-9 activity between the two groups of animals, MMP-2 activity (both the proMMP and active forms) was significantly higher in CC10-IL-13 Tg lungs compared to those from WT animals (Fig. 3A-C) . Similarly, evaluation of tissue lysates by casein gel zymography showed significantly higher MMP-12 enzymatic activity in CC10-IL-13 Tg mice (Fig. 3D) .
MMP imaging of the lungs
To address the feasibility of molecular imaging of MMP activation in the lungs, CC10-IL-13 Tg and WT mice underwent in vivo microSPECT/CT imaging with RP805, a 99m Tc-labeled tracer with specificity for activated MMPs. On visual analysis of fused images, the MMP signal was readily detectable in CC10-IL-13 Tg lungs, but not in WT animals. (Fig. 4) . This was confirmed by quantitative analysis of RP805 uptake in the lungs which showed significantly higher uptake of the tracer in CC10-IL-13 Tg mice compared to WT animals (6.90 ± 1.76, n = 13 vs. 3.06 ± 1.33 %ID/cm 3 , n = 6, respectively for CC10-IL-13 Tg and WT mice; P < 0.001).
RP805 uptake in CC10-IL-13 Tg lungs was confirmed by ex vivo planar imaging. Fig. 3A-D) . There was a significant correlation between microSPECT-derived and planar image-derived tracer uptake (r = 0.79, P < 0.001), validating our quantification methodology (Supplemental Fig. 3E ).
Specificity
The enhanced endothelial permeability associated with inflammation can lead to nonspecific uptake of the tracer. To address the specificity RP805 uptake in our model we developed a new non-binding analog by changing the hydroxamate group with Nmethyl amide group (amide analog, Supplemental Fig. 1B) . MicroSPECT/CT imaging of CC10-IL-13 Tg mice using the amide analog showed significantly lower accumulation of this control tracer in the lungs (2.87 %ID/ cm 3 ± 1.61; P < 0.001) compared to RP805 (Fig. 4) . Similarly, ex vivo planar imaging showed significantly lower uptake of this amide analog tracer in CC10-IL-13 Tg lungs (0.09 cpp/mm 2 /MBq ± 0.03; p < 0.01) compared to RP805 (Supplemental Fig. 3 ). Pre-incubation with nonlabeled precursor significantly blocked RP805 binding to CC10-IL-13 Tg lung sections, further confirming RP805 binding specificity (Supplemental Fig. 4) . CC10-IL-13 Tg mice show a spectrum of phenotypes that mirror emphysema, idiopathic pulmonary fibrosis, and asthma in humans 15, 24 . In line with the protease-anti-protease imbalance paradigm as the mediator of pulmonary remodeling in humans 24 , these phenotypes in transgenic mice are mediated, at least in part, through stimulation of matrix remodeling via upregulation and activation of different members of MMP family.
Correlates of MMP signal in the lungs
As such, the CC10-IL-13 Tg mouse is an effective experimental model for molecular imaging studies of lung inflammation and remodeling.
Beyond symptoms, current evaluation of pulmonary pathology is predominantly based on physiologic measurements (e.g., pulmonary function testing), and anatomical imaging by chest X-ray and CT. The limitations of this approach are well recognized, as the results of these tests often lag behind cellular and molecular processes that underlie the development of the disease or resolution of pulmonary pathology in response to therapeutic interventions. Quantitative imaging techniques to detect pulmonary pathophysiology, to track effectiveness of therapeutic interventions, and to advance pulmonary research are much in need. Emerging CT and MRI-based imaging techniques seek to measure gas trapping, lung volume, lung density, and airway and vessel morphology [26] [27] [28] [29] . However these techniques are incapable of tracking key molecular and cellular processes. In this regard, molecular imaging is a valuable addition to the current arsenal of lung imaging techniques. The high sensitivity of radionuclide-based molecular imaging technology (i.e., SPECT and PET) allows the detection of targets in nanomolar concentration range and is quite advantageous for this purpose.
Molecular imaging is routinely used in the clinic for detection, characterization and staging of lung cancer. A few studies have explored other applications of molecular imaging in pulmonary pathology. As such, the short term reproducibility of MMPs are a family of zinc-dependent proteases that regulate matrix remodeling and inflammation through degradation of extracellular matrix proteins, modulation of cell signaling and regulation of chemokines and growth factor function 22, 33 . Typically, MMPs are produced as inactive pro-enzymes which undergo proteolytic activation to expose a catalytic site. MMP function is regulated at several levels, including gene expression, proenzyme activation, expression of inhibitors (e.g., TIMPs, α2-macroglobulin), macromolecular complex formation, and compartmentalization. This complexity of MMP biology is reflected in differences in gene expression between transgenic and WT animals and the discordance between MMP mRNA expression and activity for specific members of MMP family. The lack of highly specific antibodies for the activated forms of MMPs and their complex biology, including the mismatch between the sites of protein synthesis and proteolytic activation, extracellular secretion, as well as uptake by neighboring cells 23 preclude accurate co-localization of activated MMPs with specific lung cells. Nevertheless, macrophages are the major source of MMP production in the lungs, although other intrinsic lung cells (e.g. epithelial cells) also contribute to this process 34 . As such, the correlation between MMP signal detected in vivo and CD68 expression in our model is not surprising and is indeed consistent with a similar observations in vascular and valvular pathology 19, 20, 35 . While the relative value of imaging specific members of MMP family versus MMP activation in general as an investigational tool can be debated, clinically this may be less relevant. A few tracers for ex vivo fluorescence-based optical imaging of specific members of MMP family have been developed 36, 37 . However, it is not clear whether the expression level of any specific member of MMP family reaches the threshold for in vivo imaging, even using by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from the most sensitive nuclear techniques. Whether imaging a specific member of MMP family in vivo is feasible and more effective than targeting MMP activation in general remains to be empirically determined.
A potential pitfall in cardiothoracic molecular imaging is the effect of respiratory and cardiac motion on signal quantification. The confounding effects of this motion, which leads to an apparent reduction in the lung signal, is especially important for focal processes and smaller regions and lesions. As such it is critical to ascertain the validity of signal quantification methodology for in vivo images. Addressing this issue, we showed a strong correlation between in vivo microSPECT and ex vivo planar imagingderived measures of RP805 uptake. Because of the diffuse nature of the pathology, respiratory motion correction of images appears to be less critical in IL-13 transgenic mice. However, this factor should be considered in molecular imaging of human lesions where regional differences in disease activity may exist. Another potential confounding factor is the difference in lung structure, density, size, content, and cellularity between normal and pathologic conditions. Indeed, traditional housekeeping gene-based normalization methodologies are not as effective in comparing CC10-IL-13 Tg and WT animals. Therefore, we relied on volume-based measurements to compare and correlate imaging and biological data in our animals. This approach rules out the possibility that the observed differences between transgenic and control animals are secondary to differences in lung volume and can be readily translated to clinical imaging. Based on the premise that changes in MMP activation precede structural changes in the lungs, MMP-targeted imaging could be used for tracking the effect of by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from
